Literature DB >> 19520589

Six independent domains are defined by geriatric assessment in elderly cancer patients.

R Stauder1, K Moser, B Holzner, B Sperner-Unterweger, G Kemmler.   

Abstract

BACKGROUND: Geriatric assessment (GA) must be integrated into treatment concepts for elderly cancer patients. Aim of this study was to assess the coverage of a large battery of GA instruments by determining the number of independent domains measured.
METHODS: Thirteen different GA scores were applied in 78 elderly tumor patients (mean age 72.9 years). Data were analyzed by exploratory factor analysis and substantiated by non-parametric correlation analyses.
RESULTS: Factor analysis yielded a six-factor solution explaining 77.1% of the total variance. The six domains identified may be described as general functioning in everyday life, health-related quality of life, co-morbidities, social support, cognition, and nutritional status. This factor structure was reasonably well confirmed by correlation analyses. Notably, WHO Performance Status, Karnofsky Index, VES-13 and PPT generally revealed high correlations with functional capacities, but only low correlations with comorbidities, social support, cognitive functioning or nutritional status.
CONCLUSIONS: From the six domains described a basis for efficient application of GA instruments in elderly cancer patients is worked out. The classical instruments WHO and KI as well as the screening scores VES-13 and PPT, while capturing physical functioning well, fail to cover several other important GA domains. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19520589     DOI: 10.1016/j.critrevonc.2009.04.010

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

Review 1.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

2.  Examining five- and ten-year survival in older women with breast cancer using cancer-specific geriatric assessment.

Authors:  Kerri M Clough-Gorr; Soe Soe Thwin; Andreas E Stuck; Rebecca A Silliman
Journal:  Eur J Cancer       Date:  2011-07-07       Impact factor: 9.162

3.  The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.

Authors:  Heidi D Klepin; Ann M Geiger; Janet A Tooze; Stephen B Kritchevsky; Jeff D Williamson; Leslie R Ellis; Denise Levitan; Timothy S Pardee; Scott Isom; Bayard L Powell
Journal:  J Am Geriatr Soc       Date:  2011-09-13       Impact factor: 5.562

4.  Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.

Authors:  J S Gewandter; L Fan; A Magnuson; K Mustian; L Peppone; C Heckler; J Hopkins; M Tejani; G R Morrow; S G Mohile
Journal:  Support Care Cancer       Date:  2013-02-28       Impact factor: 3.603

Review 5.  The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.

Authors:  Reinhard Stauder
Journal:  Ann Hematol       Date:  2012-05-01       Impact factor: 3.673

6.  Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy.

Authors:  F Hofer; K A Koinig; L Nagl; B Borjan; R Stauder
Journal:  Ann Hematol       Date:  2018-07-28       Impact factor: 3.673

7.  Development and testing of the Geriatric Care Assessment Practices (G-CAP) survey.

Authors:  Justine L Giosa; Paul Stolee; Paul Holyoke
Journal:  BMC Geriatr       Date:  2021-04-01       Impact factor: 3.921

Review 8.  Use of geriatric assessment for older adults in the oncology setting: a systematic review.

Authors:  M T E Puts; J Hardt; J Monette; V Girre; E Springall; S M H Alibhai
Journal:  J Natl Cancer Inst       Date:  2012-07-31       Impact factor: 13.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.